Send to a friend
The details you provide on this page will not be used to send unsolicited email, and will not be sold to a 3rd party. See privacy policy.
SII’s executive director for regulatory affairs, Suresh Jadhav, says that moving vaccine R&D to developing countries could eventually cut the cost of new drug development ‘by a factor of ten’. Jadhav predicts that companies in Brazil, Cuba and Indonesia will expand their R&D programmes and start creating cheaper drugs and vaccines for use in developing countries.